Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1126
- Registration Number
- NCT02516241
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2021-04-12
- Target Recruit Count
- 24
- Registration Number
- NCT02485990
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 267
- Registration Number
- NCT02319044
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02179671
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT02141347
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- F. Stephen Hodi, MD
- Target Recruit Count
- 15
- Registration Number
- NCT02141542
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT02040064
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 459
- Registration Number
- NCT02000947
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 104
- Registration Number
- NCT01975831
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Virginia Division of Hematology and Oncology, Charlottesville, Virginia, United States
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 269
- Registration Number
- NCT01938612
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.